Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Delineating SWI/SNF gene and subtype expression in cancer

Summary

This study investigated the expression of SWI/SNF chromatin remodeling complex genes and its subtypes (cBAF, PBAF, GBAF) across 33 tumor types, utilizing DNA and mRNA data from The Cancer Genome Atlas (approximately 11,000 samples). Researchers found that the expression of certain genes like ACTL6B, DPF1, DPF3, and SMARCD3 varied most among tumor types, with 10 out of 33 tumor types exhibiting distinct expression signatures. While SWI/SNF gene mutations resulted in only minor changes in their own expression, they were linked to downstream regulation of transcriptional programs associated with epigenetic regulation, particularly in colon adenocarcinoma, kidney renal clear cell carcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma. These findings could contribute to the development of biomarkers and targeted therapies.

Critical appraisal

Molecular biology. This study represents a significant molecular discovery by characterizing the expression profiles of all 29 SWI/SNF complex genes and its three subtypes (cBAF, PBAF, GBAF) across a wide range of cancers. The use of TCGA DNA and mRNA data from approximately 11,000 samples allowed for the identification of genes (ACTL6B, DPF1, DPF3, SMARCD3) with highly variable expression and distinct expression signatures in 10 tumor types. The finding that SWI/SNF mutations, while not directly affecting the complex’s gene expression, regulate downstream epigenetic transcriptional programs, particularly in specific cancers, opens avenues for understanding tumorigenesis and resistance mechanisms. This information is crucial for identifying new predictive or prognostic biomarkers and for developing targeted therapies that address these altered epigenetic pathways.

Bioinfo & AI. The study robustly leveraged the vast datasets from TCGA, encompassing DNA and mRNA data from nearly 11,000 samples across 33 tumor types. This large-scale bioinformatic approach enabled profiling the expression of all 29 SWI/SNF genes and analyzing subtype-specific expression signatures of the complex. The comparative analysis of gene expression based on tissue of origin and the mutational status of SWI/SNF genes demonstrates a strong application of omics data analysis to identify complex correlations. The results of this analysis could be integrated into clinical bioinformatic pipelines for molecular tumor characterization, helping to prioritize patients for clinical trials or therapies based on epigenetic alterations.

Clinical. The insights generated by this study have potential clinical impact in the medium term (3-5 years). By identifying distinct SWI/SNF gene expression signatures and downstream epigenetic transcriptional programs regulated by their mutations, the study lays the groundwork for developing new biomarkers. These biomarkers could be used to stratify patients, predict response to existing treatments, or identify patients likely to benefit from emerging targeted therapies that act on chromatin remodeling or epigenetic pathways. While this is a characterization study, it warrants further translational research to validate these biomarkers in clinical cohorts and design Phase I/II trials evaluating epigenetic pathway inhibitors in the identified patient subgroups.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology